Literature DB >> 25797375

Combined effects of androgen anabolic steroids and physical activity on the hypothalamic-pituitary-gonadal axis.

Jonas Hengevoss1, Marion Piechotta2, Dennis Müller3, Fabian Hanft4, Maria Kristina Parr5, Wilhelm Schänzer6, Patrick Diel7.   

Abstract

Analysing effects of pharmaceutical substances and training on feedback mechanisms of the hypothalamic-pituitary-gonadal axis may be helpful to quantify the benefit of strategies preventing loss of muscle mass, and in the fight against doping. In this study we analysed combined effects of anabolic steroids and training on the hypothalamic-pituitary-gonadal axis. Therefore intact male Wistar rats were dose-dependently treated with metandienone, estradienedione and the selective androgen receptor modulator (SARM) S-1. In serum cortisol, testosterone, 17β-estradiol (E2), prolactin, inhibin B, follicle-stimulating hormone (FSH), luteinizing hormone (LH), Insulin-like growth factor 1 (IGF-1), and thyroxine (T4) concentrations were determined. Six human volunteers were single treated with 1-androstenedione. In addition abusing and clean body builders were analysed. Serum concentrations of inhibin B, IGF-1, cortisol, prolactin, T4, thyroid-stimulating hormone (TSH), testosterone and LH were determined. In rats, administration of metandienone, estradienedione and S-1 resulted in an increase of muscle fiber diameter. Metandienone and estradienedione but not S-1 administration significantly decreases LH and inhibin B serum concentration. Administration of estradienedione resulted in an increase of E2 and S-1 in an increase of cortisol. Single administration of 1-androstenedione in humans decreased cortisol and inhibin B serum concentrations. LH was not affected. In abusing body builders a significantly decrease of LH, TSH and inhibin B and an increase of prolactin, IGF-1 and T4 was detected. In clean body builders only T4 and TSH were affected.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anabolic steroids; Hypothalamic–pituitary–gonadal axis; SARMs; Training

Mesh:

Substances:

Year:  2015        PMID: 25797375     DOI: 10.1016/j.jsbmb.2015.03.003

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  6 in total

Review 1.  Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?

Authors:  Marc J Kaufman; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Neurosci Biobehav Rev       Date:  2019-02-25       Impact factor: 8.989

2.  Anabolic steroids abuse and male infertility.

Authors:  Rabih El Osta; Thierry Almont; Catherine Diligent; Nicolas Hubert; Pascal Eschwège; Jacques Hubert
Journal:  Basic Clin Androl       Date:  2016-02-06

3.  Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study.

Authors:  Jon Jarløv Rasmussen; Christian Selmer; Peter Busch Østergren; Karen Boje Pedersen; Morten Schou; Finn Gustafsson; Jens Faber; Anders Juul; Caroline Kistorp
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

Review 4.  On the Role of Testosterone in Anxiety-Like Behavior Across Life in Experimental Rodents.

Authors:  Emese Domonkos; Július Hodosy; Daniela Ostatníková; Peter Celec
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-06       Impact factor: 5.555

5.  A prolonged hiatus in postmenopausal HRT, does not nullify the therapy's positive impact on ageing related sarcopenia.

Authors:  Gladys L Onambélé-Pearson; David J Tomlinson; Christopher I Morse; Hans Degens
Journal:  PLoS One       Date:  2021-05-05       Impact factor: 3.240

Review 6.  Sexual Activity before Sports Competition: A Systematic Review.

Authors:  Laura Stefani; Giorgio Galanti; Johnny Padulo; Nicola L Bragazzi; Nicola Maffulli
Journal:  Front Physiol       Date:  2016-06-21       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.